SLC5A2 and Hypokalemia: SGLT2 inhibitors have good safety and tolerability, with few reports regarding a decline in renal function, hypokalaemia, or hyponatremia (Zinman et al., 2015; McMurray et al., 2019; Damman et al., 2020; Mordi et al., 2020; Boorsma et al., 2021).